Biotech entity
Of the tracked stories, 2 of 4 also mention Retraction Watch, the most common co-covered peer. That works out to roughly 4 stories per week across a 7-day span. The busiest single day carried 2. clinical-trial accounts for 3 of the 4 tracked stories, while 1 other category carries the remainder.
Last mentioned: Aug 21, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 4 also mention Retraction Watch, the most common co-covered peer. That works out to roughly 4 stories per week across a 7-day span. The busiest single day carried 2. clinical-trial accounts for 3 of the 4 tracked stories, while 1 other category carries the remainder. The 7 average consequence score is above the beat benchmark of 5.9 in the same window. They are better corroborated than the beat average, carrying 2.8 original sources each against 2.5 for the same window. Nature appears in 4 tracked Biotech stories published from July 26, 2026 through August 1, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 51 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nature. Shared-story counts are live from our verified record — not editorial picks.
Shanghai Jiaotong University launches investigation
The university forms a working group to comprehensively investigate the clinical trial and the associated Nature paper.
Joint investigation report published
Science magazine and Retraction Watch release findings detailing the undisclosed death and ethical lapses, bringing the case to public attention.
University investigation launched
Shanghai Jiao Tong University School of Medicine announces a special working group to investigate and promises 'serious action'.
Investigative report published
Science and Retraction Watch publish a joint exposé revealing the death and lack of disclosure, triggering international scrutiny.
Mei receives gene-editing therapy
Six-year-old girl with rare cognitive delay condition receives spinal infusion of trillions of engineered viruses in an experimental trial.
Fatal gene-editing trial conducted
A young girl receives an experimental gene-editing treatment for a developmental-delay-linked genetic defect at Xinhua Hospital; she later dies, an outcome the ethics board deems treatment-related.
He Jiankui gene-edited babies scandal breaks
Chinese scientist He Jiankui announces the birth of the world’s first gene-edited babies, triggering global outrage and prompting China to tighten research regulations.
Biotech and pharma firms face a growing brain drain as three top U.S. cognitive scientists relocate to the U.K. amid NIH and NSF funding upheavals. A survey shows 75% of scientists are considering leaving, threatening the talent pipeline for drug discovery and clinical research.
A young girl's death in an undisclosed gene-editing trial, funded by $860,000 from her parents, has triggered an investigation at Shanghai Jiaotong University. The case exposes critical ethics gaps in China's surging biopharma sector and raises alarms for investors, partners, and regulators worldwide.
Source: yahoo.com · egyptindependent.com
Oral HIF-2α inhibitor casdatifan posted durable responses in the ARC-20 phase 1 trial of 127 heavily pretreated ccRCC patients, published in Nature. The data intensifies competition in the HIF-2α space, where Merck’s belzutifan is already approved, and sets the stage for pivotal trials.
Source: miragenews.com · news-medical.net
The death of a young patient in a Chinese gene-editing trial, hidden from a subsequent Nature publication, sends shockwaves through the biotech sector. Industry leaders must grapple with the implications for gene therapy research integrity, funding, and the race to deliver transformative neurological treatments.
Source: channelnewsasia.com · straitstimes.com
Nature is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
